Legato Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Legato Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.27M	Sell	43,874 -12,452	-22%	-$872K	0.27%	110
2026 Q1	$4.18M	Buy	56,326 +11,101	+25%	+$805K	0.38%	47
2025 Q4	$3.46M	Buy	45,225 +17,682	+64%	+$1.16M	0.3%	64
2025 Q3	$1.43M	Buy	27,543 +6,472	+31%	+$316K	0.16%	202
2025 Q2	$910K	Hold	21,071	–	–	0.11%	303
2025 Q1	$728K	Buy	21,071 +13,401	+175%	+$452K	0.1%	337
2024 Q4	$210K	Buy	+7,670	New	+$198K	0.03%	522
2021 Q3	–	Sell	-11,171	Closed	-$681K	–	206
2021 Q2	$681K	Buy	+11,171	New	+$638K	0.1%	209

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Legato Capital Management's BBIO Position: Q2 2026 in Review

Legato Capital Management reduced its BridgeBio Pharma (BBIO) stake by 22% in Q2 2026, selling an estimated $872K and leaving 43,874 shares worth $3.27M. The position accounts for 0.27% of the portfolio, ranked #110.

Legato Capital Management first reported a position in BBIO in Q2 2021 and has held it in 8 quarters since. The position peaked at $4.18M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Legato Capital Management held 43,874 shares of BridgeBio Pharma worth $3.27M as of Q2 2026.
Legato Capital Management sold 12,452 BridgeBio Pharma shares in Q2 2026, an estimated $872K.
BridgeBio Pharma made up 0.27% of Legato Capital Management's portfolio in Q2 2026, its #110 holding.
Legato Capital Management first reported a position in BridgeBio Pharma in Q2 2021 and has held it in 8 quarters since.
Legato Capital Management's BridgeBio Pharma position peaked at $4.18M in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.